NCT07133425View on ClinicalTrials.gov

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 5, 2026

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2030

Conditions
Non-Small Cell Lung CancerICI-refractory
Interventions
DRUG

SAR445877

Given by IV

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER